BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Clinical trial NCT03520920 · COMPLETED

Trial details

NCT number: NCT03520920
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma Follicular Lymphoma Diffuse Large B-Cell Lymphoma

Start date: 2018-01-04
Primary completion: 2020-08-28
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.